Students Awarded Grants
Three Gerstner Sloan-Kettering students -- Eric Alonzo, Kim Png, and Ly Vu -- have been awarded grants for their potential not only in pursuing meaningful scientific research but in playing a role in such diverse goals as fostering relationships between nations, ensuring a diverse US scientific community, and contributing to a vibrant knowledge base in Singapore.
Molecules Can Block Breast Cancer's Ability to Spread
Gerstner Sloan-Kettering faculty have identified a specific group of microRNA molecules that are responsible for controlling genes that cause breast cancer metastasis.
Newly Established Brain Tumor Center Cultivates Collaborations
Under the direction of Eric C. Holland, Gerstner Sloan-Kettering faculty member, neurosurgeon, and cancer biologist, Memorial Sloan-Kettering has established a Brain Tumor Center -- a center without walls -- housing a multidisciplinary effort that encompasses research from the laboratory to the clinic.
Thomas Kelly Appointed to National Institutes of Health Advisory Committee
Gerstner Sloan-Kettering Provost and Sloan-Kettering Institute Director Thomas J. Kelly was one of five individuals appointed to serve as members of the Advisory Committee to the National Institutes of Health Director.
James Allison Elected to the Institute of Medicine
James P. Allison, Gerstner Sloan-Kettering faculty member and Chair of the Immunology Program in the Sloan-Kettering Institute, has been elected a member of the Institute of Medicine. Dr. Allison is a leader in the field of immunology, particularly in developing ways to help the immune system recognize and destroy cancer cells.
Charles Sawyers Named to Howard Hughes Medical Institute
Charles L. Sawyers, Gerstner Sloan-Kettering Faculty Member and Chair of Memorial Sloan-Kettering's Human Oncology and Pathogenesis Program, is one of 15 patient-oriented researchers to be appointed a Howard Hughes Medical Institute (HHMI) investigator. Dr. Sawyers' work examines how signaling pathway abnormalities in cancer cells can be exploited as targets for new cancer drugs.
